Holzkirchen, Germany, January 16, 2014 – Sandoz announced it has received marketing authorization in Hungary for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.

The product was first approved in Denmark on December 18th, 2013 with subsequent marketing authorizations received earlier this week also in Germany and Sweden.

The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device.

Hungary has approved the 50- …